Worth reading
64In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
100000
SharesWording
Conditional
How definitive the wording is.Details of issuance or disposal
Progress report on the forced exercise of paid stock options (Series 5 Stock Acquisition Rights)
Who receives how much
Number of shares scheduled for issuance 100,000 shares
4 directors of the Company80,000 shares
1 employee of the Company20,000 shares
The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.
Amount of funds to be raised
Scheduled payment amount: ¥38,600,000; estimated net proceeds: Not disclosed
Specific use of funds
Business-related fundsAmount Specific allocation of funds has not been determined
Existing Shares and Increase
+0.35%Rate of increase
28,604,378 shares28,704,378Shares
0.35%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Initial exercise price: ¥386. Adjustment provisions for the exercise price: Not disclosed
Exercise period
Start Date 1 April 2025 / End date 31 March 2029
Number of Stock Acquisition Rights
Total number issued 8,700 rights / Unexercised balance 1,000 rights
Offering structure
Major shareholders after the offering
Name SK FUND Investment Limited Liability Partnership / Shareholding ratio 6.97%Name 株式会社 IT / Shareholding ratio 6.17%Name 株式会社 Medical Management Consulting / Shareholding ratio 5.11%Name Tasaka Daisaku (田坂 大作) / Shareholding ratio 4.47%Name Mano Kenji (間野 賢治) / Shareholding ratio 3.48%Name 株式会社スマイル・オン / Shareholding ratio 3.16%Name 株式会社トライユニティ / Shareholding ratio 3.16%Name Imamura Kai (今村 海) / Shareholding ratio 2.86%Name Yasui Hirotomo (安井 浩倫) / Shareholding ratio 2.32%Name Imamura Go (今村 豪) / Shareholding ratio 2.19%
Categories and Number of Persons Covered
Category Directors of the Company / Number of Employees 4 (initially 6) / Number of allocated shares 80,000 shares (remaining), Category Employees of the Company / Number of Employees 1 / Number of allocated shares 20,000 shares (remaining)
Payment date
By 31 March 2029
Most recent equity financing
Timing 29 October 2024 / Type Public offering of Stock Acquisition Rights (paid stock options) / Amount Not disclosed
Impact on Business Performance
If the Series 5 Stock Acquisition Rights are formally exercised, total proceeds of approximately ¥38 million will be raised. The funds are expected to be allocated to business-related purposes, but the specific allocation and other details have not been determined.
| Item | Details |
|---|---|
| Type of issuance or disposal | Progress report on the forced exercise of paid stock options (Series 5 Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | Number of shares scheduled for issuance 100,000 shares |
| Amount of funds to be raised | Scheduled payment amount: ¥38,600,000; estimated net proceeds: Not disclosed |
| Specific use of funds | Details Business-related funds / Amount Specific allocation of funds has not been determined / Scheduled timing of expenditures Not disclosed |
| Payment date | By 31 March 2029 |
| Intended allottee | Category 4 directors of the Company / Remaining rights 800 rights / Number of underlying shares 80,000 shares, Category 1 employee of the Company / Remaining rights 200 rights / Number of underlying shares 20,000 shares |
| Dilution Rate | 0.35% |
| Total number of issued shares | 28,604,378 shares → 28,704,378 shares（0.35%） |
| Exercise price | Initial exercise price: ¥386. Adjustment provisions for the exercise price: Not disclosed |
| Exercise period | Start Date 1 April 2025 / End date 31 March 2029 |
| Number of Stock Acquisition Rights | Total number issued 8,700 rights / Unexercised balance 1,000 rights |
| Categories and Number of Persons Covered | Category Directors of the Company / Number of Employees 4 (initially 6) / Number of allocated shares 80,000 shares (remaining), Category Employees of the Company / Number of Employees 1 / Number of allocated shares 20,000 shares (remaining) |
| Most recent equity financing | Timing 29 October 2024 / Type Public offering of Stock Acquisition Rights (paid stock options) / Amount Not disclosed |
| Major shareholders after the offering | Name SK FUND Investment Limited Liability Partnership / Shareholding ratio 6.97%, Name 株式会社 IT / Shareholding ratio 6.17%, Name 株式会社 Medical Management Consulting / Shareholding ratio 5.11%, Name Tasaka Daisaku (田坂 大作) / Shareholding ratio 4.47%, Name Mano Kenji (間野 賢治) / Shareholding ratio 3.48%, Name 株式会社スマイル・オン / Shareholding ratio 3.16%, Name 株式会社トライユニティ / Shareholding ratio 3.16%, Name Imamura Kai (今村 海) / Shareholding ratio 2.86%, Name Yasui Hirotomo (安井 浩倫) / Shareholding ratio 2.32%, Name Imamura Go (今村 豪) / Shareholding ratio 2.19% |
| Impact on Business Performance | If the Series 5 Stock Acquisition Rights are formally exercised, total proceeds of approximately ¥38 million will be raised. The funds are expected to be allocated to business-related purposes, but the specific allocation and other details have not been determined. |
Items this document does not state (13)
Issue price and disposal priceTotal issue valueEstimated issuance expensesIntended allottee's holding policyBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of Conduct
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The average closing share price over the most recent 21 trading days, including 28 October 2026, was ¥113.90, below ¥115.80, which is 30% of the exercise price of ¥386. Accordingly, the forced exercise conditions were met.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.